EQS-News: Marinomed Biotech AG announces results for the first half year of 2025

EQS-News: Marinomed Biotech AG / Key word(s): Half Year Results
   Marinomed Biotech AG announces results for the first half year of 2025

   17.09.2025 / 13:48 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    

   Marinomed Biotech AG announces results for the first half year of 2025

    

     • Revenues amounted to EUR 7.2 million in the first half of 2025 (H1
       2024: EUR 2.4 Mio.)
     • EBIT of EUR 21.0 Mio., which includes a restructuring gain
     • Financing secured by the latest capital measures

    

   Korneuburg, Österreich, September 17, 2025 -  Marinomed Biotech AG
   (VSE:MARI) significantly increased both revenue and earnings in the first
   half of 2025. Revenue amounted to EUR 7.2 million (H1 2024: EUR 2.4
   million). Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2
   million), significantly influenced by other operating income of EUR 19.3
   million, which includes a restructuring gain of EUR 18.9 million. Cash
   flow from operating activities was slightly negative at EUR –0.2 million.
   Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5
   million, compared to EUR 0.9 million in the previous year. Balance sheet
   total decreased to EUR 7.6 million (December 31, 2024: EUR 8.2 million).

    

   "The sale of the Carragelose business has significantly strengthened our
   financial base. We see this as an important intermediate step in advancing
   our pipeline of Marinosolv projects and building the foundation for
   sustainable growth. With the targeted approval of Budesolv, we have made
   significant operational progress in recent months. We are well on track.
   Our operational progress is also reflected in the development of our key
   figures—cash flow from operating activities has improved, however, still
   slightly negative. The recently announced capital measures have further
   strengthened our financial base," added Gabriele Ram, CFO of Marinomed.

    

   "The planned convertible bond in the amount of EUR 2.5 million, as well as
   the capital increase of EUR 1.1 million announced yesterday not only
   strengthen our negotiating position with potential licensing partners for
   our development projects Budesolv and Tacrosolv, but also enable us to
   advance more rapidly on the operational side. Marinomed's current
   financial planning does not include any further capital measures,“
   according to Andreas Grassauer, CEO of Marinomed.”

    

   Selected financial figures for H1 2025

                          All amounts in kEUR H1 2025  H1 2024
                                     Revenues  7,178.1  2,418.7
                      Operating result (EBIT) 20,971.8 -3,182.4
                                 R&D Expenses -1,400.0 -2,386.9
   Cash flow utilized by operating activities   -214.5 -1,828.9

    

    

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: https://www.marinomed.com:
   [1]https://www.marinomed.com.

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [2]pr@marinomed.com
   E-Mail: [3]ir@marinomed.com

    

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forwardlooking statements are only valid as of the date they
   are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise.

   ══════════════════════════════════════════════════════════════════════════

   17.09.2025 CET/CEST This Corporate News was distributed by EQS Group.
   www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 2199130


    
   End of News EQS News Service


   2199130  17.09.2025 CET/CEST

   https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2199130&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2199130&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. mailto:pr@marinomed.com
   3. mailto:ir@marinomed.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print